Comparison of cilostazol versus ticlopidine therapy after stent implantation

Seong Wook Park, Cheol Whan Lee, Hyun Sook Kim, Hyo Jung Lee, Hoon Ki Park, Myeongki Hong, Jae Joong Kim, Seung Jung Park

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The aim of this study was to evaluate the efficacy of cilostazol for prevention of stent thrombosis compared with ticlopidine. Cilostazol is a potent antiplatelet agent with less serious side effects. However, few data are available about the effect of cilostazol in preventing stent thrombosis after coronary stent implantation. Four hundred ninety patients selected for elective stent placement were randomized to receive aspirin plus ticlopidine (n = 243) or aspirin plus cilostazol (n = 247) for 1 month. Clinical and laboratory evaluations were performed at regular interval. There were no differences in baseline characteristics between the 2 groups. During the first 30 days after stent implantation, major cardiac events or adverse drug effects were similar between the 2 groups: ticlopidine (2.9%) vs cilostazol (1.6%) group, p = NS; stent thrombosis (0.4% vs 0.8%, p = NS, respectively), myocardial infarction (0.4% vs 0.8%, p = NS), severe leukopenia (1.2% vs 0%, p = NS), severe thrombocytopenia (0.4% vs 0%, p = NS), and cerebral hemorrhage (0.4% vs 0 %, p = NS). Adverse effects led to drug withdrawal in 7 patients in the ticlopidine group (2.9%) and in 5 in the cilostazol group (2.0%). There was no death during the follow-up period. Thus, aspirin plus cilostazol may be an effective antithrombotic regimen with comparable results to aspirin plus ticlopidine after elective coronary stenting. Copyright (C) 1999 Excerpta Medica Inc.

Original languageEnglish
Pages (from-to)511-514
Number of pages4
JournalAmerican Journal of Cardiology
Volume84
Issue number5
DOIs
Publication statusPublished - 1999 Sep 1

Fingerprint

Ticlopidine
Stents
Aspirin
Therapeutics
Thrombosis
Coronary Thrombosis
Platelet Aggregation Inhibitors
Cerebral Hemorrhage
Leukopenia
cilostazol
Drug-Related Side Effects and Adverse Reactions
Thrombocytopenia
Myocardial Infarction
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Park, Seong Wook ; Lee, Cheol Whan ; Kim, Hyun Sook ; Lee, Hyo Jung ; Park, Hoon Ki ; Hong, Myeongki ; Kim, Jae Joong ; Park, Seung Jung. / Comparison of cilostazol versus ticlopidine therapy after stent implantation. In: American Journal of Cardiology. 1999 ; Vol. 84, No. 5. pp. 511-514.
@article{f967b694ad884592afa1620e6af4aca8,
title = "Comparison of cilostazol versus ticlopidine therapy after stent implantation",
abstract = "The aim of this study was to evaluate the efficacy of cilostazol for prevention of stent thrombosis compared with ticlopidine. Cilostazol is a potent antiplatelet agent with less serious side effects. However, few data are available about the effect of cilostazol in preventing stent thrombosis after coronary stent implantation. Four hundred ninety patients selected for elective stent placement were randomized to receive aspirin plus ticlopidine (n = 243) or aspirin plus cilostazol (n = 247) for 1 month. Clinical and laboratory evaluations were performed at regular interval. There were no differences in baseline characteristics between the 2 groups. During the first 30 days after stent implantation, major cardiac events or adverse drug effects were similar between the 2 groups: ticlopidine (2.9{\%}) vs cilostazol (1.6{\%}) group, p = NS; stent thrombosis (0.4{\%} vs 0.8{\%}, p = NS, respectively), myocardial infarction (0.4{\%} vs 0.8{\%}, p = NS), severe leukopenia (1.2{\%} vs 0{\%}, p = NS), severe thrombocytopenia (0.4{\%} vs 0{\%}, p = NS), and cerebral hemorrhage (0.4{\%} vs 0 {\%}, p = NS). Adverse effects led to drug withdrawal in 7 patients in the ticlopidine group (2.9{\%}) and in 5 in the cilostazol group (2.0{\%}). There was no death during the follow-up period. Thus, aspirin plus cilostazol may be an effective antithrombotic regimen with comparable results to aspirin plus ticlopidine after elective coronary stenting. Copyright (C) 1999 Excerpta Medica Inc.",
author = "Park, {Seong Wook} and Lee, {Cheol Whan} and Kim, {Hyun Sook} and Lee, {Hyo Jung} and Park, {Hoon Ki} and Myeongki Hong and Kim, {Jae Joong} and Park, {Seung Jung}",
year = "1999",
month = "9",
day = "1",
doi = "10.1016/S0002-9149(99)00368-9",
language = "English",
volume = "84",
pages = "511--514",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

Park, SW, Lee, CW, Kim, HS, Lee, HJ, Park, HK, Hong, M, Kim, JJ & Park, SJ 1999, 'Comparison of cilostazol versus ticlopidine therapy after stent implantation', American Journal of Cardiology, vol. 84, no. 5, pp. 511-514. https://doi.org/10.1016/S0002-9149(99)00368-9

Comparison of cilostazol versus ticlopidine therapy after stent implantation. / Park, Seong Wook; Lee, Cheol Whan; Kim, Hyun Sook; Lee, Hyo Jung; Park, Hoon Ki; Hong, Myeongki; Kim, Jae Joong; Park, Seung Jung.

In: American Journal of Cardiology, Vol. 84, No. 5, 01.09.1999, p. 511-514.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of cilostazol versus ticlopidine therapy after stent implantation

AU - Park, Seong Wook

AU - Lee, Cheol Whan

AU - Kim, Hyun Sook

AU - Lee, Hyo Jung

AU - Park, Hoon Ki

AU - Hong, Myeongki

AU - Kim, Jae Joong

AU - Park, Seung Jung

PY - 1999/9/1

Y1 - 1999/9/1

N2 - The aim of this study was to evaluate the efficacy of cilostazol for prevention of stent thrombosis compared with ticlopidine. Cilostazol is a potent antiplatelet agent with less serious side effects. However, few data are available about the effect of cilostazol in preventing stent thrombosis after coronary stent implantation. Four hundred ninety patients selected for elective stent placement were randomized to receive aspirin plus ticlopidine (n = 243) or aspirin plus cilostazol (n = 247) for 1 month. Clinical and laboratory evaluations were performed at regular interval. There were no differences in baseline characteristics between the 2 groups. During the first 30 days after stent implantation, major cardiac events or adverse drug effects were similar between the 2 groups: ticlopidine (2.9%) vs cilostazol (1.6%) group, p = NS; stent thrombosis (0.4% vs 0.8%, p = NS, respectively), myocardial infarction (0.4% vs 0.8%, p = NS), severe leukopenia (1.2% vs 0%, p = NS), severe thrombocytopenia (0.4% vs 0%, p = NS), and cerebral hemorrhage (0.4% vs 0 %, p = NS). Adverse effects led to drug withdrawal in 7 patients in the ticlopidine group (2.9%) and in 5 in the cilostazol group (2.0%). There was no death during the follow-up period. Thus, aspirin plus cilostazol may be an effective antithrombotic regimen with comparable results to aspirin plus ticlopidine after elective coronary stenting. Copyright (C) 1999 Excerpta Medica Inc.

AB - The aim of this study was to evaluate the efficacy of cilostazol for prevention of stent thrombosis compared with ticlopidine. Cilostazol is a potent antiplatelet agent with less serious side effects. However, few data are available about the effect of cilostazol in preventing stent thrombosis after coronary stent implantation. Four hundred ninety patients selected for elective stent placement were randomized to receive aspirin plus ticlopidine (n = 243) or aspirin plus cilostazol (n = 247) for 1 month. Clinical and laboratory evaluations were performed at regular interval. There were no differences in baseline characteristics between the 2 groups. During the first 30 days after stent implantation, major cardiac events or adverse drug effects were similar between the 2 groups: ticlopidine (2.9%) vs cilostazol (1.6%) group, p = NS; stent thrombosis (0.4% vs 0.8%, p = NS, respectively), myocardial infarction (0.4% vs 0.8%, p = NS), severe leukopenia (1.2% vs 0%, p = NS), severe thrombocytopenia (0.4% vs 0%, p = NS), and cerebral hemorrhage (0.4% vs 0 %, p = NS). Adverse effects led to drug withdrawal in 7 patients in the ticlopidine group (2.9%) and in 5 in the cilostazol group (2.0%). There was no death during the follow-up period. Thus, aspirin plus cilostazol may be an effective antithrombotic regimen with comparable results to aspirin plus ticlopidine after elective coronary stenting. Copyright (C) 1999 Excerpta Medica Inc.

UR - http://www.scopus.com/inward/record.url?scp=0032855354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032855354&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(99)00368-9

DO - 10.1016/S0002-9149(99)00368-9

M3 - Article

VL - 84

SP - 511

EP - 514

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -